Idorsia Ltd (IDRSF)
- Globe Newswire
JERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertension
Ad hoc announcement pursuant to Art. 53 LR Idorsia receives a positive opinion from the Committee for Medicinal Products for Human Use for JERAYGO™ (aprocitentan) as the first and only endothelin receptor antagonist for the treatment of resistant hypertension in adult patients in combination with at least three antihypertensive medicinal products.A CHMP positive opinion is one of the final steps before marketing authorization can be granted by the European Commission – a final decision is expect
- Globe Newswire
Idorsia publishes an invitation to a bondholder meeting
Ad hoc announcement pursuant to Art. 53 LR A bondholder meeting will take place on May 6, 2024, to vote on proposals to amend the terms of the outstanding convertible bonds maturing on July 17, 2024, including an extension of the maturity by six months. Allschwil, Switzerland – April 23, 2024Idorsia Ltd (SIX: IDIA) today announced that it has published an invitation to a bondholder meeting for holders of its outstanding convertible bonds maturing on July 17, 2024 (ISIN: CH0426820350) (the Bonds)
- Globe Newswire
Idorsia publishes a Financial Status required for an upcoming bondholder meeting
Ad hoc announcement pursuant to Art. 53 LR Unaudited Financial Status as of March 31, 2024, required for an upcoming bondholder meeting, now available on the company websiteBondholder meeting now planned for early May as the company continues to engage with bondholders Allschwil, Switzerland – April 17, 2024Idorsia Ltd (SIX: IDIA) today announced that its Unaudited Financial Status as of March 31, 2024, required for an upcoming bondholder meeting is available on the company website at the follow
